<DOC>
	<DOCNO>NCT01904721</DOCNO>
	<brief_summary>This safety efficacy study bimatoprost male subject androgenic alopecia ( AGA ) .</brief_summary>
	<brief_title>A Safety Efficacy Study Bimatoprost Men With Androgenic Alopecia ( AGA )</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Mild moderate male pattern baldness ( androgenic alopecia ) ongoing hair loss least 1 year Willingness maintain hair style , length hair color study Willingness microdottattoo apply scalp ( Stage 2 ) Drug alcohol abuse within 12 month HIV positive Received hair transplant scalp reduction Use hair weave , hair extension wigs within 3 month Use minoxidil ( oral topical ) and/or low level light treatment `` comb '' hair growth within last 6 month , expect use study Application topical steroid nonsteroidal antiinflammatory drug ( NSAIDs ) scalp within 4 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>